Overview
* Dexcom Q3 2025 revenue grows 22% yr/yr, beating analyst expectations
* Adjusted EPS for Q3 2025 beats analyst expectations, reflecting positive operational performance
* Company raises fiscal year 2025 revenue guidance, indicating confidence in continued growth
Outlook
* Dexcom ( DXCM ) raises 2025 revenue guidance to $4.630-$4.650 bln, reflecting 15% growth
* Company expects 2025 non-GAAP gross profit margin of approximately 61%
* Dexcom ( DXCM ) anticipates 2025 adjusted EBITDA margin of 29-30%
Result Drivers
* AI-POWERED FEATURE - Launched AI-powered meal logging in Stelo and Dexcom G7 app, enhancing personalized glucose insights
* EXPANDED ACCESS - Expanded access to Dexcom G7 for insulin users under Ontario Drug Benefit Program in Canada
* STRATEGIC INITIATIVES - Submitted Dexcom Smart Basal insulin titration module to FDA, aiming to enhance product offerings
Key Details
Metric Beat/Mis Actual Consensu
s s
Estimate
Q3 Beat $1.21 $1.17
Revenue bln bln (25
Analysts
)
Q3 Beat $0.61 $0.56
Adjusted (24
EPS Analysts
)
Q3 Beat $242.50 $226.76
Adjusted mln mln (18
Net Analysts
Income )
Q3 Beat $272.90 $271.25
Adjusted mln mln (21
Operatin Analysts
g Income )
Q3 $741.30
Adjusted mln
Gross
Profit
Q3 Gross $731.40
Profit mln
Q3 $242.50
Operatin mln
g Income
Analyst Coverage
* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 25 "strong buy" or "buy", 5 "hold" and no "sell" or "strong sell"
* The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy"
* Wall Street's median 12-month price target for Dexcom Inc ( DXCM ) is $100.00, about 31.8% above its October 29 closing price of $68.18
Press Release:
For questions concerning the data in this report, contact [email protected]. For any other questions or feedback, contact .
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)